Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Racial Differences in the Time-Course Oxidative Stress Responses to Acute Exercise
Results may vary, but many users notice changes within a few weeks of consistent use
WEDNESDAY, July 23, 2025 (HealthDay News) -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin, according to a study published online July 22 in BMJ Open Diabetes Research & Care.Mingyang Sun, from the People's Hospital of Zhengzhou University in China, and colleagues conducted a retrospective cohort study using data from a global health research network between 2004 and 2024 to examine the comparative effectiveness of GLP-1 RAs and metformin in reducing dementia risk
Choose Safety Profile Adverse reactions reported in 3% of Wegovy 2.4 mg injection-treated adolescent patients aged 12 years and older with obesity and more frequently than with placebo 1 Gastrointestinal disorders were the most frequent adverse events with Wegovy ( 62% vs 42% with placebo) 2.3% of patients treated with Wegovy vs 1.5% of patients who received placebo discontinued treatment as a result of gastrointestinal adverse events 6 Mean increases in resting heart rate of 1.2 beats per minute from baseline were observed with patients taking Wegovy vs a decrease of 2.3 beats per minute with placebo 6 Adverse reactions with Wegovy treatment in pediatric patients aged 12 years and older were similar to those reported in adults
